TrialClinical cardiology2014

Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy.

Jennifer G Robinson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.